INCMGA00012 + Palbociclib

Phase 2Active

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Well-differentiated/Dedifferentiated Liposarcoma

Conditions

Well-differentiated/Dedifferentiated Liposarcoma

Trial Timeline

Jun 17, 2020 → Jun 1, 2026

NCT ID

NCT04438824

About INCMGA00012 + Palbociclib

INCMGA00012 + Palbociclib is a phase 2 stage product being developed by Incyte for Well-differentiated/Dedifferentiated Liposarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT04438824. Target conditions include Well-differentiated/Dedifferentiated Liposarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04438824	Phase 2	Active	Jun 17, 2020	Jun 1, 2026	Well-differentiated/Dedifferentiated Liposarcoma